Talk:Tofacitinib

This is the talk page for discussing improvements to the Tofacitinib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tofacitinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Deletion of alopecia content seems excessive

[deletion of alopecia content] seems excessive if the content is supported by the sources ? Any objections or conditions to adding back ? - Rod57 (talk) 22:47, 30 January 2016 (UTC)[reply]

FDA approved for psoriatic arthritis

Tofacitinib for PsA: From Phase III to Approval - In mid-December, tofacitinib was approved for use in active psoriatic arthritis says FDA approved it for psoriatic arthritis in Dec 2017. - Rod57 (talk) 12:43, 29 December 2017 (UTC)[reply]

Still needs update?

Anyone know what the February 2017 update request was about, and whether it was fulfilled or not? Myoglobin (talk) 17:15, 24 January 2018 (UTC)[reply]

Not sure why this tag was added, but as tofacitinib is approved now, it should contain information about contraindications, interactions, pharmacokinetics, and probably a more extensive side effects section (see MOS:MED#Drugs, treatments, and devices). Some long-term editors would also argue for removing information about (phase 2) studies. Also, the article seems to say that the drug isn't approved in the EU, which isn't true now [1]. --ἀνυπόδητος (talk) 18:39, 24 January 2018 (UTC)[reply]